We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — Primary generalized tonic-clonic seizures ...
An FDA-cleared wrist-worn device reliably detects convulsive seizures in epilepsy monitoring units but can miss focal ...
FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) ...
A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...
More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...
A seizure occurs when there is abnormal electrical activity in the brain. There are different types of seizures depending on where and how much brain activity is affected. If someone is seizing make ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results